PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Brunn, D.* ; Turkowski, K.* ; Günther, S.* ; Weigert, A.* ; Muley, T.* ; Kriegsmann, M.* ; Winter, H.* ; Dammann, R.H.* ; Stathopoulos, G.T. ; Thomas, M.* ; Guenther, A.* ; Grimminger, F.* ; Pullamsetti, S.S.* ; Seeger, W.* ; Savai, R.*

Interferon regulatory factor 9 promotes lung cancer progression via regulation of versican.

Cancers 13:208 (2021)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Transcription factors can serve as links between tumor microenvironment signaling and oncogenesis. Interferon regulatory factor 9 (IRF9) is recruited and expressed upon interferon stimulation and is dependent on cofactors that exert in tumor-suppressing or oncogenic functions via the JAK-STAT pathway. IRF9 is frequently overexpressed in human lung cancer and is associated with decreased patient survival; however, the underlying mechanisms remain to be elucidated. Here, we used stably transduced lung adenocarcinoma cell lines (A549 and A427) to overexpress or knockdown IRF9. Overexpression led to increased oncogenic behavior in vitro, including enhanced proliferation and migration, whereas knockdown reduced these effects. These findings were confirmed in vivo using lung tumor xenografts in nude mice, and effects on both tumor growth and tumor mass were observed. Using RNA sequencing, we identified versican (VCAN) as a novel downstream target of IRF9. Indeed, IRF9 and VCAN expression levels were found to be correlated. We showed for the first time that IRF9 binds at a newly identified response element in the promoter region of VCAN to regulate its transcription. Using an siRNA approach, VCAN was found to enable the oncogenic properties (proliferation and migration) of IRF9 transduced cells, perhaps with CDKN1A involvement. The targeted inhibition of IRF9 in lung cancer could therefore be used as a new treatment option without multimodal interference in microenvironment JAK-STAT signaling.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
6.639
1.292
4
5
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Adenocarcinoma ; Interferon Regulatory Factor 9 (irf9) ; Lung Cancer ; Tumor Microenvironment (tme) ; Type I Interferons (ifns) ; Versican (vcan)
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 2072-6694
Zeitschrift Cancers
Quellenangaben Band: 13, Heft: 2, Seiten: , Artikelnummer: 208 Supplement: ,
Verlag MDPI
Verlagsort St Alban-anlage 66, Ch-4052 Basel, Switzerland
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Lung Research
PSP-Element(e) G-501600-003
Förderungen European Research Council (ERC) Consolidator Grant
DFG, SFB CRC 1213
German Center for Lung Research (DZL)
Cardio-Pulmonary Institute (CPI)
Institute for Lung Health (ILH)
Rhön Klinikum AG grant
Von-Behring-Röntgen-Stiftung
Verein zur Förderung der Krebsforschung in Gieβen e.V
Max Planck Society
DOI 10.3390/cancers13020208
WOS ID WOS:000611109700001
Scopus ID 85099392841
PubMed ID 33430083
Erfassungsdatum 2021-03-26
[➜Korrektur melden]